In a phase I clinical trial, tumor-infiltrating lymphocyte therapy combined with the anti–PD-1 drug nivolumab was considered safe and tolerable—and exhibited preliminary signs of efficacy—in patients with stage IV or recurrent non–small cell lung cancer.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.